Challenges and priorities in the management of HIV/HBV and HIV/HCV coinfection in resource-limited settings

Seminars in Liver Disease

Volumn 32, Issue 2, 2012, Pages 147-157

  Easterbrook, Philippa ^a   Sands, Anita ^b   Harmanci, Hande ^c  

^a UNAIDS   (Switzerland)

^b Department of Essential Medicines and Health Products ^*  (Switzerland)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

HIV hepatitis B coinfection; HIV hepatitis C coinfection; resource limited settings

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

AFRICA SOUTH OF THE SAHARA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AWARENESS; CAUSE OF DEATH; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH PROMOTION; HEPATITIS B; HEPATITIS C; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RATE; LIVER FIBROSIS; LIVER SCINTISCANNING; MASS IMMUNIZATION; MASS SCREENING; MIXED INFECTION; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PREVALENCE; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; RESOURCE MANAGEMENT; SOUTHEAST ASIA; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

ANTIVIRAL AGENTS; COINFECTION; DEVELOPING COUNTRIES; DISEASE MANAGEMENT; HEALTH RESOURCES; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HIV; HIV INFECTIONS; HUMANS; PRACTICE GUIDELINES AS TOPIC; WORLD HEALTH ORGANIZATION;

EID: 84863224225     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0032-1316476     Document Type: Article

References (68)

1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine: 2012; 30 12 2212 2219
2. Lavanchy D. Chronic viral hepatitis as a public health issue in the world. Best Pract Res Clin Gastroenterol: 2008; 22 6 991 1008
3. Madhava V, Burgess C, Drucker E. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect Dis: 2002; 2 5 293 302
4. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis: 2005; 5 9 558 567
5. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol: 2006; 45 4 529 538
6. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol: 2006; 44 1, Suppl S6 S9
7. Hoffmann CJ, Thio CL. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis: 2007; 7 6 402 409
8. Modi AA, Feld JJ. Viral hepatitis and HIV in Africa. AIDS Rev: 2007; 9 1 25 39
9. Scharschmidt BF, Held MJ, Hollander HH., et al. Hepatitis B in patients with HIV infection: relationship to AIDS and patient survival. Ann Intern Med: 1992; 117 10 837 838
10. Sinicco A, Raiteri R, Sciandra M., et al. Coinfection and superinfection of hepatitis B virus in patients infected with human immunodeficiency virus: no evidence of faster progression to AIDS. Scand J Infect Dis: 1997; 29 2 111 115
11. El-Serag HB, Giordano TP, Kramer J, Richardson P, Souchek J. Survival in hepatitis C and HIV co-infection: a cohort study of hospitalized veterans. Clin Gastroenterol Hepatol: 2005; 3 2 175 183
12. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA: 2002; 288 2 199 206
13. Thio CL, Seaberg EC, Skolasky R Jr., et al. Multicenter AIDS Cohort Study. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet: 2002; 360 9349 1921 1926
14. Hadigan C, Kottilil S. Hepatitis C virus infection and coinfection with human immunodeficiency virus: challenges and advancements in management. JAMA: 2011; 306 3 294 301
15. Bodsworth N, Donovan B, Nightingale BN. The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men. J Infect Dis: 1989; 160 4 577 582
16. Colin JF, Cazals-Hatem D, Loriot MA., et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology: 1999; 29 4 1306 1310
17. Gilson RJ, Hawkins AE, Beecham MR., et al. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS: 1997; 11 5 597 606
18. Benhamou Y, Bochet M, Di Martino V., et al. The Multivirc Group Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology: 1999; 30 4 1054 1058
19. Puoti M, Bonacini M, Spinetti A., et al. HIV-HCV Coinfection Study Group Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J Infect Dis: 2001; 183 1 134 137
20. Graham CS, Baden LR, Yu E., et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis: 2001; 33 4 562 569
21. Konopnicki D, Mocroft A, de Wit S., et al. EuroSIDA Group Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS: 2005; 19 6 593 601
22. Puoti M, Spinetti A, Ghezzi A., et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr: 2000; 24 3 211 217
23. Núñez M. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology: 2010; 52 3 1143 1155
24. Labarga P, Soriano V, Vispo ME., et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis: 2007; 196 5 670 676
25. Zöllner B, Petersen J, Puchhammer-Stöckl E., et al. Viral features of lamivudine resistant hepatitis B genotypes A and D. Hepatology: 2004; 39 1 42 50
26. Benhamou Y, Bochet M, Thibault V., et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology: 1999; 30 5 1302 1306
27. DeSimone J, Pomerantz R, Babinchak T. Inflammatory reactions in HIV-1 infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med: 2000; 133 447 454
28. Shelburne S, Hamill R, Rodriguez-Barradas M., et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore): 2002; 81 3 213 227
29. Weber R, Sabin C, Friis-Moller N., et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med: 2006; 166 15 1632 1641
30. Salmon-Ceron D, Lewden C, Morlat P., et al. Mortality 2000 study group Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol: 2005; 42 6 799 805
31. Ford N, Kirby C, Singh K., et al. Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis. Bulletin of the World Health Organisation 2012. Available at: http://www.who.int/bulletin/online-first/11-097147.pdf. Accessed January 12, 2012
32. Viral hepatitis: global policy. London World Hepatitis Alliance: 2011;. Available at: http://www.worldhepatitisalliance.org/Policy/2010PolicyReport. aspx. Accessed January 12, 2012
33. Viral hepatitis. WHA63.18. Sixty-third World Health Assembly. Agenda item 11.12. Geneva World Health Organization: 2010;. Available at: http://apps.who.int/gb/ebwha/pdf-files/WHA63/A63-R18-en.pdf. Accessed January 12, 2012
34. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol: 2009; 50 2 227 242
35. Liaw YF, Leung N, Kao JH., et al. Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int: 2008; 2 3 263 283
36. Rockstroh JK, Bhagani S, Benhamou Y., et al. EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med: 2008; 9 2 82 88
37. Soriano V, Puoti M, Sulkowski M., et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS: 2007; 21 9 1073 1089
38. Thursz M, Cooke GS, Hall AJ. Hepatitis B treatment in resource poor settings: time for action. Trop Med Int Health: 2010; 15 1 2 4
39. Wiersma ST, McMahon B, Pawlotsky JM., et al. World Health Organization Department of Immunization, Vaccines and Biologicals. Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus. Liver Int: 2011; 31 6 755 761
40. Ford N, Singh K, Cooke GS., et al. Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS. Clin Infect Dis: 2012; 54 10 1465 1472
41. Heenan R, Wiersma S, Vitori M, Cheung A, Easterbrook P. Significant variation in recommendations for management of HIV-Hepatitis B and C (HIV-HBV and HIV-HCV) co-infection: A Survey of National Guidelines from Resource Limited Settings. Abstract presented at: International Aids Conference; July 22-27, 2012; Washington, DC
42. Davis LG, Weber DJ, Lemon SM. Horizontal transmission of hepatitis B virus. Lancet: 1989; 1 8643 889 893
43. Kew MC. Progress towards the comprehensive control of hepatitis B in Africa: a view from South Africa. Gut: 1996; 38 Suppl 2 S31 S36
44. Kiire CF. The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: a view from tropical and subtropical Africa. Gut: 1996; 38 Suppl 2 S5 S12
45. Custer B, Sullivan SD, Hazlet TK., et al. Global Epidemiology of Hepatitis B Virus. J Clin Gastroenterol: 2004; 38 3 S158 S168
46. Nur YA, Groen J, Elmi AM, Ott A, Osterhaus AD. Prevalence of serum antibodies against bloodborne and sexually transmitted agents in selected groups in Somalia. Epidemiol Infect: 2000; 124 1 137 141
47. Herrero Martínez E. Hepatitis B and hepatitis C co-infection in patients with HIV. Rev Med Virol: 2001; 11 4 253 270
48. Candotti D, Mundy C, Kadewele G, Nkhoma W, Bates I, Allain JP. Serological and molecular screening for viruses in blood donors from Ntcheu, Malawi: high prevalence of HIV-1 subtype C and of markers of hepatitis B and C viruses. J Med Virol: 2001; 65 1 1 5
49. Matee MI, Lyamuya EF, Mbena EC., et al. Prevalence of transfusion-associated viral infections and syphilis among blood donors in Muhimbili Medical Centre, Dar es Salaam, Tanzania. East Afr Med J: 1999; 76 3 167 171
50. Ansa VO, Udoma EJ, Umoh MS, Anah MU. Occupational risk of infection by human immunodeficiency and hepatitis B viruses among health workers in south-eastern Nigeria. East Afr Med J: 2002; 79 5 254 256
51. Hauri AM, Armstrong GL, Hutin YJ. The global burden of disease attributable to contaminated injections given in health care settings. Int J STD AIDS: 2004; 15 1 7 16
52. Njouom R, Pasquier C, Ayouba A., et al. Low risk of mother-to-child transmission of hepatitis C virus in Yaounde, Cameroon: the ANRS 1262 study. Am J Trop Med Hyg: 2005; 73 2 460 466
53. Broderick AL, Jonas MM. Hepatitis B in children. Sem Liver Dis: 2003; 23 1 59 68
54. Pasquier C, Njouom R, Ayouba A., et al. Distribution and heterogeneity of hepatitis C genotypes in hepatitis patients in Cameroon. J Med Virol: 2005; 77 3 390 398
55. Scheiblauer H, El-Nageh M, Diaz S., et al. Performance evaluation of 70 hepatitis B virus (HBV) surface antigent (HBsAg) assays from around the world by a geographically diverse panel with an array of HBV genotypes and HBsAg subtypes. Vox Sang: 2010; 98 581
56. Allain JP, Candotti D, Soldan K., et al. The risk of hepatitis B virus infection by transfusion in Kumasi, Ghana. Blood: 2003; 101 6 2419 2425
57. Callahan JD, Constantine NT, Kataaha P, Zhang X, Hyams KC, Bansal J. Second generation hepatitis C virus assays: performance when testing African sera. J Med Virol: 1993; 41 1 35 38
58. Castera L. Non-invasive assessment of liver fibrosis in chronic hepatitis C. Hepatol Int: 2011; 5 2 625 634
59. Baranova A, Lal P, Birerdinc A, Younossi ZM. Non-invasive markers for hepatic fibrosis. BMC Gastroenterol: 2011; 11 91
60. Degos F, Perez P, Roche B., et al. FIBROSTIC study group Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol: 2010; 53 6 1013 1021
61. Nunes D, Fleming C, Offner G., et al. HIV infection does not affect the performance of non-invasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J Acquir Immune Defic Syndr: 2005; 40 5 538 544
62. Cacoub P, Carrat F, Bédosa P., et al. Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: The fibrovic studyANRS HCO2. J Hepatol: 2008; 48 5 765 773
63. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach - 2010 revision. Available at: http://whqlibdoc.who.int/publications/2010/ 9789241599764-eng.pdf. Accessed January 12, 2012
64. Bessesen M, Ives D, Condreay L, Lawrence S, Sherman KE. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis: 1999; 28 5 1032 103ENGLoratory/evaluations/110322-pqdx-007-pq-overview- document-v4.pdf
65. Diagnostics and Laboratory Technology. Geneva: World Health Organization; 2011;. Available at: http://www.who.int/diagnostics
66. Diagnostics and Laboratory Technology. Geneva: World Health Organization; 2012;. Available at: http://www.who.int/diagnostics
67. Easterbrook PJ. HIV immune reconstitution syndrome in sub-Saharan Africa. AIDS: 2008; 22 5 643 645
68. Viljoen J, Gampini S, Danaviah S., et al. World Health Organization/ANRS 1289 Kesho Bora Study Group Dried blood spot HIV-1 RNA quantification using open real-time systems in South Africa and Burkina Faso. J Acquir Immune Defic Syndr: 2010; 55 3 290 298